i have a patient i want to start on Glow

To start a patient on Glow, which appears to involve the use of BPC-157, consider the following information: 1. **BPC-157 Overview**: BPC-157 is a synthetic pentadecapeptide derived from human gastric juice, primarily studied in preclinical rodent models. It has shown potential effects such as promoting angiogenesis, modulating growth factor pathways, and enhancing fibroblast migration, which may contribute to accelerated healing of various tissues, including tendons and gastrointestinal lining [1]. 2. **Dosing Protocol**: For tissue repair and recovery, a common dosing regimen for BPC-157 is 250 mcg subcutaneously twice daily for 4 weeks, followed by 250 mcg once daily for maintenance. It is important to reconstitute BPC-157 with bacteriostatic water and refrigerate after mixing [5]. 3. **Safety and Monitoring**: Human safety data for BPC-157 are limited, and it is not approved as a drug in many regions. Monitoring for injection-site reactions and inflammatory markers (e.g., hs-CRP) is recommended at baseline and every 4 weeks during treatment [5]. 4. **Combination with Other Agents**: BPC-157 may be combined with TB-500 (2 mg subcutaneously twice weekly for 6 weeks) to support connective tissue and tendon recovery [5]. 5. **Regulatory Considerations**: The regulatory status of BPC-157 varies by jurisdiction, and sourcing and purity are practical concerns that should be addressed before use [1]. Please remember that this information is for decision support only and does not constitute a treatment recommendation or directive.